Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) th edition staging criteria
Extensive disease per criteria of the International Association for the Study of Lung Cancer (IASLC)-American Joint Committee on Cancer (AJCC) TNM staging system
Subjects with histologically confirmed advanced, progressive, well-differentiated nonfunctional NET of the pancreas, lung or gastrointestinal (GI) tract per the th International Association for the Study of Lung Cancer classification (IASLC) or the American Joint Committee on Cancer (AJCC) staging handbook, th edition
Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) th edition proposed staging criteria
Eligible patients must have appropriate staging studies identifying them as specific subsets of the revised International Association for the Study of Lung Cancer (IASLC) stage IA based on the following combination of Tumor Node Metastasis (TNM) staging: Ta,N,M or Tb,N,M
International Association for the Study of Lung Cancer (IASLC) version , stage IV disease; or recurrence after prior surgery or radiotherapy
Stage IV or Recurrent NSCLC (per the th International Association for the Study of Lung Cancer (IASLC) classification)
International Association for the Study of Lung Cancer (IASLC) version , subset of stage IIIA single station (N) disease; specifically Ta-T, N(+) with no invasion of key structures (e.g., chest wall or diaphragm)
